NCT00132028View on ClinicalTrials.gov

Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions

Adult Favorable Prognosis Hodgkin LymphomaAdult Lymphocyte Depletion Hodgkin LymphomaAdult Lymphocyte Predominant Hodgkin LymphomaAdult Mixed Cellularity Hodgkin LymphomaAdult Nodular Lymphocyte Predominant Hodgkin LymphomaAdult Nodular Sclerosis Hodgkin LymphomaAdult Unfavorable Prognosis Hodgkin LymphomaRecurrent Adult Hodgkin Lymphoma

Interventions

DRUG

vorinostat

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

78245

Southwest Oncology Group (SWOG) Research Base, San Antonio

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00132028 - Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter